Matthew Correa

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Joshua D. Hansen, Matthew Correa, Mark A. Nagy et al. · Journal of Medicinal Chemistry · 2020 · 204 citations · Full text

Hematological Malignancy, Novel Therapy, Medicine +15

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

Joshua D. Hansen, Matthew Correa, Matt Alexander et al. · Journal of Medicinal Chemistry · 2021 · 138 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Cell Death +17

Protein Degradation via CRL4^CRBN Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1

Joshua D. Hansen, Kevin R. Condroski, Matthew Correa et al. · Journal of Medicinal Chemistry · 2017 · 76 citations

Drug Target, Protein Assembly, Molecular Biology +19

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Deborah S. Mortensen, Sophie Perrin-Ninkovic, Graziella Shevlin et al. · Journal of Medicinal Chemistry · 2015 · 72 citations · Full text

Drug Target, Kinase Inhibitors, Pharmacotherapy +16

Vulnerability and risk: climate change and water supply from California’s Central Valley water system

Patrick Ray, Sungwook Wi, Andrew Schwarz et al. · Climatic Change · 2020 · 55 citations

Engineering, Water Resources, Geography +4